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ABSTRACT
Objective: This study was undertaken to characterize the pharmacokinetics of zidovudine (ZDV)
and ZDV-glucuronide (ZDVG) in the material and fetal circulations of the rhesus monkey.
Methods: Cannulas were placed in the maternal external jugular and the fetal internal jugular
and carotid artery in 8 pregnant monkeys at 120-130 days gestation. ZDV (3.5 mg/kg) was adminis-
tered to 5 monkeys and ZDVG (3.5 mg/kg) to 3 monkeys as single intravenous bolus infusions
through the maternal catheter. Maternal and fetal blood samples were collected every 20 min for the
first 2 h and then every hour for the next 4 h. Maternal and fetal concentrations ofZDV andZDVG
were determined using high-performance liquid chromatography (HPLC) with ultraviolet (UV)
detection.
Results: In monkeys who received ZDV, the terminal half-life (T1/2) forZDV was 37 -+ 15 and
33 -+ 13 min in the maternal and fetal compartments, respectively. The apparent T1/2 for maternal
ZDVG was 124 +_ 44 and 142 +- 50 min in the maternal and fetal compartments, respectively. Peak
levels ofZDV and ZDVG in the fetal compartment were reached 40 min after injection. The mean
fetal/maternal concentration ratios for ZDV and ZDVG ranged from 0.20 -+ 0.20 at 20 min to a
maximum of 0.74 + 1.0 at 120 min and from 0.28 + 0.08 at 20 min to 1.4 _+ 1.3 at 180 min, respec-
tively. In monkeys who received ZDVG, the T1/2 for ZDVG in the maternal and fetal compart-
ments was 47 _+ 26 and 119 _+ 164 min, respectively. ZDVG reached its peak in the fetal compart-
ment at 60 min post-injection. The fetal/maternal ratio ranged from 0.08-+ 0.11 at 20 min to
4.2 -+ 4.2 at 180 min post-injection.
Conclusions: These data demonstrate that 1) ZDV and ZDVG rapidly cross the placenta to the
fetal compartment, 2) ZDV crosses more rapidly than ZDVG, and 3) some metabolism ofZDV to
ZDVG occurs in the fetal compartment. (C) 1994 Wiley-Liss, Inc.
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n the United States there are an estimated 6,000
pregnancies annually in women who are human
immunodeficiency virus (HIV) positive. Treat-
ment with zidovudine (ZDV) is recommended for
non-pregnant HIV-infected individuals whose CD4
cell counts drop below 500/mm3. 2 In the pregnant
patient, treatment with ZDV is not specifically rec-
ommended until the CD4 cell count drops below
200/mm3. 3 Some feel ZDV treatment should be
offered during pregnancy when CD4 counts drop
below 500/mm3. 3 Regardless of when treatment is
initiated, it is apparent that an increasing number
of pregnant women and their fetuses are being ex-
posed to ZDV.
4
While there is considerable information on the
pharmacology and metabolism of ZDV in men,
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there are limited data on the pharmacokinetics of
ZDV in the pregnant mother and her fetus.
Hankins et al.
5 examined maternal, fetal, and am-
niotic fluid levels of ZDV and ZDV-glucuronide
(ZDVG) after multiple oral doses in near-term
pregnant baboons. In their study, maternal and
fetal levels of ZDV and ZDVG were not signifi-
cantly different at sampling. Ho.wever, amniotic
fluid levels of ZDV and ZDVG were significantly
greater than maternal levels. The authors do not
give sampling time after oral dose and no fetal or
maternal pharmacokinetic information can be de-
rived from their study. A recent phase I study of
ZDV in women in the third trimester of preg-
nancy
6 demonstrated the pharmacokinetic parame-
ters to be similar to non-pregnant adults. Unfortu-
nately, no information on fetal pharmacokinetics
can be obtained in human pregnancies.
In the present study, we utilized a chronically
cannulated rhesus monkey model to assess the phar-
macokinetics of ZDV and ZDVG in both the ma-
ternal and fetal circulations after maternal injection
ofZDV or ZDVG.
SUBJECTS AND METHODS
Primate Husbandry
Rhesus monkeys (Macacca mulatta; n 8) of 120-
130 days gestation (term 167 days) were stud-
ied. Weights ranged from 6.4 to 11.8 kg and all
were drug naive. The animals were individually
caged in climate-controlled rooms and provided
with water ad libitum and food twice daily. The
study was approved by the Institutional Animal
Care and Use Committee.
Catheterization
After the monkey was sedated with ketamine hy-
drochloride (15 mg/kg, i.m.), a cuffed endotra-
cheal tube was placed and anesthesia maintained
using a combination of halothane, nitrous oxide,
and oxygen. Maternal stability was assured by con-
tinuous monitoring of heart rate and blood pres-
sure. The monkey’s neck was prepared and draped
for surgery. The skin was incised over the right
sternocleidomastoid, and the maternal external jug-
ular vein was exposed and cannulated with a polyvi-
nyl catheter, which was advanced to the level of the
superior vena cava. The catheter was then tunneled
subcutaneously over the right scapula and exterior-
ized at a point midway between the scapulae.
The fetal position and placental location were
determined using real-time ultrasonography. A
midline incision was made through the abdominal
wall after the maternal abdomen was sterilely pre-
pared and draped. A 3-4 cm transverse uterine
incision was made over the fetal head. The chorion
and amnion were incised.after removal of the amni-
otic fluid, which was stored at 37C. The fetal skin
overlying the sternocleidomastoid muscle was ele-
vated into the uterine incision. A 2 cm incision was
made and a self-retaining retractor placed. The
fetal internal jugular vein and carotid artery were
exposed and catheterized using polyvinyl catheters.
The fetal neck and uterus were closed in layers and
the amniotic fluid was replaced. The fetal catheters
were then tunneled subcutaneously and exteriorized
at the same point as the maternal catheter. The
abdomen was closed in layers and the monkey placed
in a vest with a mobile tether to allow blood collec-
tion without anesthesia.
Drug Injection and Blood Collection
ZDV (3.5 mg/kg; 3’-azido-3’-deoxythymidine;
Sigma Chemical Co., St. Louis, MO) was given as
a bolus injection through the maternal catheter in 5
animals after they had fully recovered from gener-
alized anesthesia. ZDVG (3.5 mg/kg; Sigma Chem-
ical Co.) was given to 3 other animals as a bolus
injection. Each ZDVG animal received 2 doses of
ZDVG 24 h apart. Maternal and fetal samples were
collected every 20 min for the first 2 h and then
every hour for the next 4 h.
ZDV and ZDVG Assay
Serum concentrations ofZDV and its major metab-
olite ZDVG were determined by solid-phase (car-
tridge C18 columns: Bond Elut, Analytichem In-
ternational, Harbor City, CA) extraction of each
serum sample and subsequent analysis by high-
performance liquid chromatography (HPLC) with
ultraviolet (UV) detection (modified from Good et
al.7). Briefly, a 50 I1 aliquot of each extracted
sample was injected onto a Supelcosil LC-18-S col-
umn [250 4.6 mm; 5 Im particle size (Supelco,
Bellefonte, PA)]. The mobile phase consisted of
0.5 M KHzPO4 (pH 2.7) and CH3CN (88:12,
v/v) at a low rate of 1.0 ml/min. The UV detector
was set at a sensitivity of 0.02 AUFS and 254 mm
wavelength. Retention times for the internal stan-
dard (3’-azido-3’-deoxyuridine, Sigma Chemical
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Fig. I. Concentrations (mean -
SEM) ofZDV in maternal and fetal circulations following maternal
administration ofZD (3.5 mg/kg) at time 0; n 5.
Co.), ZDV, and ZDVG were approximately 4.0,
7.3, and 10.9 min, respectively. Concentrations
were determined by comparison of peak areas with
those of standards using a programmed integrator
interfaced with the UV detector. Detection limits
for ZDV and ZDVG were 0.008 and 0.01 pg/ml,
respectively. Values were linear through 10 g/ml
of authentic ZDV and ZDVG standards. Intra-as-
say variation was 5.1% for ZDV and 5.9% for
ZDVG.
Statistics
Pharmacokinetic parameters were estimated using
a non-compartmental model and the computer-mod-
eling program MK MODEL. The terminal half-
life (T 1/2) was estimated using the log-linear model
with the least-squares regression of the terminal
portion of the plasma concentration curve utilizing
the formula T1/2 0.693/ke, where ke is the elim-
ination rate constant. Using the iterated data, we
estimated the clearance (C1) and volume of distri-
bution (Vd) by dividing the dose of the drug by the
area under the curve and substituting this value
into the formula T1/2 0.693"Vd/CI. Wilcoxon
sign-rank and rank-sum tests were used where ap-
propriate. P < 0.05 was considered to be signifi-
cant.
RESULTS
The concentration profiles for ZDV and ZDVG in
the maternal and fetal circulations for animals re-
ceiving ZDV are shown in Figures and 2. Figure
3 shows the maternal and fetal concentrations of
ZDVG in animals who received ZDVG. Table 1
shows the fetal/maternal ratio over the sampling
interval for the animals given ZDV and ZDVG. If
the serum concentration in the numerator or de-
nominator was zero, the time value was not used in
the calculation of the ratios. Tables 2 and 3 summa-
rize the pharmacokinetic parameter estimates for
ZDV and ZDVG. In animals receiving ZDVG,
complete data were not obtained in monkey 3 for
maternal levels after the first dose and the fetal
levels after the second dose. Other placental metab-
olites of AZT have been reported8’9 and were not
sought in this study.
In the animals receiving ZDV, the maternal and
fetal T1/2 for ZDVG were significantly longer than
for ZDV (P < 0.016). Peak fetal levels of ZDV
and ZDVG were both reached at 40 min post-
injection. In animals receiving ZDVG, peak levels
ofZDVG in the fetal compartment were reached at
60 min. The fetal/maternal ZDVG ratio was con-
sistently higher than that of ZDV.
DISCUSSION
ZDV is being used with increasing frequency in the
treatment of pregnant women with acquired immu-
nodeficienc syndrome (AIDS). 3’4 To date there is
limited information on the in vivo placental trans-
port ofZDV and its major glucuronidated metabo-
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Fig. 2. Concentrations (mean SEM) ofZDVG in maternal and fetal circulations following mater-
nal administration ofZD (3.5 mg/kg) at time 0; n 5.
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Fig. 3. Concentrations (mean +- SEM) ofZDVG in maternal and fetal circulations following mater-
nal administration ofZDYG (3.5 mg/kg) at time 0; n 3.
lite ZDVG in pregnancy. The rhesus monkey
model, with a placentation very similar to the hu-
man, provides a useful approach to the pharmaco-
kinetic study of ZDV and ZDVG in pregnancy.
The model provides useful quantitative informa-
tion as to the elimination of the parent drug and its
metabolite in the maternal compartment, as well as
its transfer across the placenta and disposition in the
fetal circulation. However, it is limited as to mech-
anistic data on the nature of the placental transfer
process. The latter is best investigated using the
isolated perfused placental cotyledon system, as em-
ployed by us8 and others9’ 10 earlier.
Using the in vivo model, we show clearly that 1)
ZDV is removed rapidly from the maternal circula-
tion and appears quickly in the fetal plasma, 2)
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TABLE I. Fetal/maternal ratio
Monkeys given
Time Monkeys given ZDV ZDVG
(min) ZD (n) ZDVG (n) ZDVG (n)
20 0.20 0.2 (5) 0.28 0.08 (5) 0.08 _+ 0. (4)
40 0.40 +_ 0.33 (5) 0.67 o. 17 (5) 0.52 +_ 0.61 (4)
60 0.35 0.21 (5) 0.81 0.31 (5) 2.17 _+ 0.99 (4)
80 0.68 -+ 0.46 (5) I. 19 +_ 0.76 (5) 2.65 -+ 1.7 (4)
100 0.65 0.69 (5) 1.12 -+ 0.92 (5) 2.47 +- 0.93 (4)
120 0.74 1.0 (5) 1.19 0.70 (5) 2.72 +_ 0.71 (4)
180 0.48 -+ 0.68 (5) 1.43 _+ 1.3 (5) 4.19 -+ 4.2 (3)
240 0.45 0.50 (3) 1.42 1.7 (5) 2.32 +- 1.9 (3)
300 0.86 (I) 0.70 _+ 0.32 (4) 1.45 +_ 0.64 (2)
360 0.92 (I) 0.76 0.73 (3)
ZDVG is generated rapidly as a result of ZDV
metabolism in the maternal compartment, and 3)
ZDVG crosses the placenta into the fetal circula-
tion, albeit apparently more slowly than ZDV.
The T1/2 ofZDV in the maternal circulation is
comparable to values reported earlier in non-preg-
6,12 nant
11 and pregnant women, as well as in the
pregnant monkey model.
13 Moreover, the clear-
ance and volume of distribution of ZDV in our
studies approximate the data of Lopez-Anaya et
al.
13 in the pregnant monkey and O’Sullivan et al.
6
in pregnant women. The plasma binding ofZDV is
low;
1 hence, the low albumin concentration seen
in pregnancy should have no effect on ZDV clear-
ance. It appears, therefore, that the pharmacokinet-
ics ofZDV in pregnancy are similar to those seen in
non-pregnant patients. Moreover, in our model,
there was rapid formation of ZDVG from injected
ZDV, with peak maternal ZDVG already evident
on initial sampling. The T1/2 of ZDVG in the
maternal circulation after ZDV administration was
much longer than the T1/2 of ZDV. This may be
explained by ZDVG derivation from ZDV. This
interpretation is consistent with lower ZDVG than
ZDV concentrations in maternal plasma and by a
shorter ZDVG T1/2 in maternal plasma when the
agent is administered as ZDVG. In other studies, a
rapid formation of ZDVG from ZDV was also
noted after ZDV administration, although the half-
life of both drugs was very similar.
1 Similarly, in
our studies, clearances of administered ZDV and
ZDVG in the maternal circulation were almost iden-
tical.
Both ZDV and ZDVG appeared rapidly in the
fetal circulation after ZDV administration. The
T1/2 of ZDV in the fetal compartment was not
significantly different from that in maternal circu-
lation. In order to determine whether the ZDVG
present in the fetal circulation is a result of placental
transfer or fetal metabolism, we looked at the mon-
keys given ZDVG alone. After ZDVG administra-
tion to the mother, peak ZDVG in the fetal circula-
tion was noted at 60 min. ZDVG disappeared more
slowly than ZDV from the fetal circulation and the
fetal/maternal ZDVG ratio was consistently greater
than the ZDV ratio. The fetal/maternal ZDVG ra-
tio after maternal ZDVG administration was also
lower at 20 and 40 min than after ZDV administra-
tion, but this was substantially reversed thereafter.
The most likely explanations for these composite
findings are that the transfer ofZDVG from mater-
nal to fetal circulations is slower than ZDV passage
across the placenta and some metabolism ofZDV to
ZDVG occurs in the fetal compartment. This is
notwithstanding the known relative immaturity of
fetal hepatic enzymes from glucuronidation.
14-16
Moreover, the rapid clearance ofZDVG from the
maternal circulation and the slower transfer of
ZDVG across the placenta probably contribute to
the retention of this metabolite in the fetus and the
increased fetal/maternal ratio. Other investigators
5
have reported high levels of ZDVG in fetal serum
and amniotic fluid ofpregnant monkeys given mul-
tiple oral doses ofZDV and have proposed that the
amniotic fluid may serve as a reservoir for ZDVG.
Verification of this overall concept will require in-
fusions of both ZDV and ZDVG into thefetal com-
partment with monitoring of relative rates of trans-
fer of each substance into the maternal circulation
and into fetal bile and urine (amniotic fluid). Pre-
liminary data in our unit, however, using the per-
fused isolated placental cotyledon support a more
rapid diffusion of ZDV than of ZDVG across the
human placenta. This is consistent with the greater
polarity ofZDVG8’9 and with the concept that these
drugs cross the placenta passively.
8-10
While transfer of animal data to clinical medi-
cine is difficult, our data suggest that ZDV dosing
does not need to be modified in pregnancy as ZDV
should not accumulate in the fetal compartment.
While ZDVG may accumulate in this compart-
ment, this should not be clinically important as
long as the metabolite remains inactive.
In conclusion, our data along with those of the
previously cited investigators suggest that bothZDV
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TABLE 2. Pharmacokinetic parameter estimates in monkeys given ZDV
TV:z (min)
Monkey No. Maternal ZDV Fetal ZD Maternal ZDYG Fetal ZDVG
Maternal ZDV
Vd (ml/kg) CI (ml/min/kg)
45 28 148 229 667 12
2 56 54 169 138 806 8
3 22 37 52 120 379 13
4 23 25 125 103 487 16
5 37 20 123 120 981 39
Mean 37 33 124 142 664 18
SD 15 13 44 50 242 12
TABLE 3. Pharmacokinetic parameter estimates in
monkeys given ZDVG
TV2 (min) Maternal ZDYG
Monkey Maternal Fetal Vd CI
No. ZDVG ZDVG (ml/kg) (ml/min/kg)
42 51 1,931 39
37 42 428 10
2 12 36 26 20
70 413 840 13
3 54
74 1,417 13
Mean 47 119 928 19
SD 26 164 761 12
and ZDVG rapidly appear in the fetal circulation
following maternal ZDV injection. Placental trans-
fer most likely occurs by passive diffusion with
ZDV crossing more rapidly than ZDVG crosses.
ZDVG may then accumulate in the fetal compart-
ment with amniotic fluid serving as a reservoir.
Fetal ZDVG accumulation appears to result from
diffusion of maternal ZDVG and from fetal metab-
olism ofZDV accompanied by slow back diffusion
of fetal ZDVG and its decreased excretion by fetal
organs.
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